Alzamend Neuro, Inc. (ALZN)
1.97
0.00 (0.00%)
USD |
NASDAQ |
Feb 10, 14:24
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 6.186M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -80.80% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | 1.414 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | -- |
Profile
| Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA. |
| URL | http://www.alzamend.com |
| Investor Relations URL | https://ir.alzamend.com/ |
| HQ State/Province | Georgia |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA. |
| URL | http://www.alzamend.com |
| Investor Relations URL | https://ir.alzamend.com/ |
| HQ State/Province | Georgia |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |